| 1 |
Simonetto D A, Liu M, Kamath P S．Portal Hypertension and Related Complications：Diagnosis and Management [J]．Mayo Clinic Proceedings，2019，94(4): 714-726.
|
| 2 |
Minano C, Garcia-Tsao G．Clinical pharmacology of portal hypertension [J]．Gastroenterol Clin North Am，2010，39(3): 681-695.
|
| 3 |
Turco L, Garcia-Tsao G．Portal Hypertension：Pathogenesis and Diagnosis [J]．Clin Liver Dis，2019，23(4): 573-587.
|
| 4 |
Püschel GP.Control of hepatocyte metabolism by sympathetic and parasympathetic hepatic nerves [J]．Anat Rec A Discov Mol Cell Evol Biol，2004，280(1): 854-867.
|
| 5 |
高啸，张芳杰，晏维，等．肝纤维化肝组织中肾上腺素能受体的表达研究[J]．中国组织化学与细胞化学杂志，2006，15(6): 598-602.
|
| 6 |
Muñoz-Ortega MH, Llamas-Ramírez RW, Romero-Delgadillo NI，et al.Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth FactorβSecretion [J]．Gut Liver，2016，10(1): 101-108.
|
| 7 |
Yang Y Y, Lin H C．Alteration of intrahepatic microcirculation in cirrhotic livers [J]．JCMA，2015，78(8): 430-437.
|
| 8 |
Mcconnell M, Iwakiri Y．Biology of portal hypertension [J]．Hepatol Int，2018，12(Suppl 1): 11-23.
|
| 9 |
Garcia-Tsao G, Abraldes JG, Berzigotti A，et al.Portal hypertensive bleeding in cirrhosis：Risk stratification，diagnosis，and management：2016 practice guidance by the American Association for the study of liver diseases [J]．Hepatology，2017，65(1): 310-335.
|
| 10 |
Lebrec D, Poynard T, Hillon P，et al.Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis：a controlled study [J]．N Engl J Med，1981，305(23): 1371-1374.
|
| 11 |
Giannelli V, Lattanzi B, Thalheimer U，et al.Beta-blockers in liver cirrhosis [J]．Ann Gastroenterol，2014，27(1): 20-26.
|
| 12 |
De Franchis R．Expanding consensus in portal hypertension：Report of the Baveno VI Consensus Workshop：Stratifying risk and individualizing care for portal hypertension [J]．J Hepatol，2015，63(3): 743-752.
|
| 13 |
Bunchorntavakul C, Reddy K R．Pharmacologic Management of Portal Hypertension [J]．Clin Liver Dis，2019，23(4): 713-736.
|
| 14 |
Yoon KT, Liu H, Lee SS.β-blockers in advanced cirrhosis：more friend than enemy [J]．Clin Mol Hepatol，2020.
|
| 15 |
Dubuisson L, Desmoulière A, Decourt B，et al.Inhibition of rat liver fibrogenesis through noradrenergic antagonism [J]．Hepatology，2002，35(2): 325-331.
|
| 16 |
Lin JC, Peng YJ, Wang SY，et al.Sympathetic Nervous System Control of Carbon Tetrachloride-Induced Oxidative Stress in Liver through alpha-Adrenergic Signaling [J]．Oxid Med Cell Longev，2016，2016: 3190617.
|
| 17 |
Cervantes-Garcia D, Cuellar-Juarez AG, Borrego-Soto G，et al.Adenoviral-bone morphogenetic protein-7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model[J]．Mol Med Rep，2017，16(6): 9431-9440.
|
| 18 |
Serna-Salas S A, Navarro-González Y D, Martínez-Hernández S L，et al.Doxazosin and Carvedilol Treatment Improves Hepatic Regeneration in a Hamster Model of Cirrhosis [J]．BioMed Res Int，2018，2018: 4706976.
|
| 19 |
Oben JA, Roskams T, Yang S，et al.Hepatic fibrogenesis requires sympathetic neurotransmitters [J]．Gut，2004，53(3): 438-445.
|
| 20 |
刘娜，张晓岚，梁传栋，等．肝纤维化过程中去甲肾上腺素各受体亚型表达的动态变化[J]．中华肝脏病杂志，2009，17(9): 653-656.
|